The prognosis of patients with some kinds of cancers whose patients are often found unresectable upon diagnosis is still dismal. In these fields, development of a new therapeutic modality is needed and gene therapy represents one promising strategy. So far, numerous cancer gene therapy clinical trials based on these principles have been carried out and have shown the safety of such modalities, but have fallen short of the initial expectations to cure cancers. In this review, we would like to make a problem-oriented discussion of current status of cancer gene therapy research by using mainly gastrointestinal cancers as an example.
Introduction
Cancer is a major public health issue especially in developed countries. Because of efforts directed at early detection and improvement of therapeutic measures, the prognosis of some cancers has improved (1). On the other hand, the prognosis of patients with some types of cancers that are unresectable when diagnosed, is still dismal (1) (2) (3) (4) . This clearly indicates the need for developing a new therapeutic approach and gene therapy represents one promising strategy. Gene therapy researchers have focused on disease entities with dismal prognosis including lung and pancreatic cancers. Initially, gene therapy encompassed the treatment of disease due to the impaired function of a certain gene by restoring that particular gene (5). However, as the development of gene delivery strategies progressed, the definition of this concept has been dramatically expanded to include various schemes for the therapy of target diseases. Thus, gene therapy could be better defined as "treatment of disease by introducing a gene with therapeutic effect or manipulating the disease-related gene". Moreover, a related field known as virotherapy or viral oncolysis is quickly emerging, which exploits advanced virology along with viral vector design for gene therapy to eradicate cancer through the use of replicative viruses.
In this review, we would like to discuss the current obstacles for the realization of cancer gene therapy and various efforts to overcome those obstacles. Since these subjects are so diverse, they will be discussed mainly by using gastrointestinal cancers as an example.
Current Situation of Cancer Gene Therapy
Since the initial promise of curing a disease is by manipulating genes related to the disease itself (6, 7), numerous basic experiments have been performed and a number of clinical trials have been conducted. In the early era of gene therapy, many believed that gene therapy would easily cure most diseases. At that time, cancer was not the exception to this promise. While gene therapy clinical trials finally showed promising therapeutic outcomes in a few diseases a few years ago (8, 9) , gene therapy of cancer still remains challenging. Various cancer gene therapy approaches have been developed in an attempt to correct genetic abnormalities, to specifically drive toxin-encoding genes to kill the tumors, or to stimulate anti-tumor immunity of the host (10) (11) (12) (13) (14) (15) (16) (17) (18) . Numerous cancer gene therapy clinical trials based on these principles have been carried out to date and have shown the safety of such modalities, but have fallen short of the initial expectations to cure cancers. Of note, the clinical trials employing in vivo gene delivery demonstrated extremely limited tumor transduction frequencies and suggested that this limitation may represent a fundamental barrier to realizing the benefits of cancer gene therapy (19) (20) (21) (22) . Since any gene therapy approach is fundamentally based on the ability to deliver the therapeutic gene to target cells with a requisite level of efficiency (19, 20, 23, 24) , adequate tumor transduction is a key factor that must be addressed for realization of clinically usable cancer gene therapy strategies. Especially, cancer gene therapy requires high efficiency because the tumor can reemerge from the residual viable cancer cells after incomplete therapy. In this context, it is hard to say that the systems used in those trials had required a transduction efficiency to confer the therapeutic effect. That is why so many efforts were made to achieve the initial promise of cancer gene therapy.
Obstacles to the Success of Cancer Gene Therapy
Amongst many points to be improved, the following three points have been identified as major problems which are currently hampering the realization of the promise of gene therapy in the field of cancer.
The first point is the choice of effector genes. The effector needs to possess a strong cytocidal effect in the cancer cells in order to confer a therapeutic effect. In addition, the effectors which can affect surrounding cells (bystander effect) are preferred since the in vivo transduction efficiency even with most efficient vectors can not reach 100%. On the other hand, if the effector genes show selective effect in cancer cells, it dramatically eases the burden of selectivity, which otherwise needs to be achieved by the selectivity of the gene delivery methods.
The second point is the method of gene delivery. There are various methods for gene delivery including viral and nonviral methods. Whatever method we select, we need to achieve efficient gene delivery in order to yield a requisite level of effector expression which is needed for the therapeutic outcome. In addition, many effectors are not selective for cancer. In other words, many effectors used in cancer gene therapy kill not only cancer cells but also non-cancer cells if they are expressed at more than a certain level. In this case, we need to configure the selectivity machinery into the vector to mitigate toxicity due to ectopic expression of effectors. Various efforts have been made in order to improve the vectors.
The third point is the interval endpoint. Although achieving some kind of anti-tumor effects is the ultimate goal of cancer gene therapy, those effects often become evident in a relatively later stage of the clinical process. In order to obtain functional information in an earlier stage and to make a clinical trial safer, it is necessary to establish a way to attain predictive information in advance to the anti-tumor effect.
Effector Gene
Various strategies have been investigated in the field of cancer gene therapy (Table I ). The contents of this table cover most of the relatively common effectors used in this field while it does not necessarily cover all methods since new effectors are reported every month. Cancer gene therapy is categorized into two distinct groups depending on the target cell: i) anti-tumor therapy based on direct cell killing and ii) anti-tumor therapy by manipulating host cells. Some of the transgenes used for the first category are tumor selective while others are not. For example, mutation compensation therapy with wildtype (wt) p53 expression is based on the concept that mutation of the proapoptotic p53 gene in cancer cells makes those cells selectively susceptible for wt-p53 mediated apoptosis (25). In this case, expression does not need to be limited to cancer cells since the transgene does not harm normal cells. On the contrary, so-called "suicide gene therapy" with a transgene to activate a prodrug requires selectivity of transgene expression since this method kills all the cells once the prodrug is converted to its active form regardless of the nature of the cells (26, 27) . The second category of cancer gene therapy achieves a therapeutic effect by manipulating host cells, including immunogene therapy to enhance the immune reaction of the host against tumor cells by activating immune cells or enhancing antigen presentation (18, 28, 29) . Other methods in this category involve the modification of the blood supply to the tumor environment (30) and alteration of the surrounding stromal cell condition (31). This second group of strategies does not necessarily require stringent expression selectivity because the expressing cells are different from the target cells.
Mutation Compensation
In many cancers the lack in functionality of proapoptotic moiety due to the mutation or deletion of a gene such as p53 has been frequently observed. This property provides a profit for the survival of cancer cells. Most interestingly, transcomplementation of such a defective gene induces apoptosis in a tumor selective manner (25). Since normal cells express such moieties, these effector genes do not harm normal cells. In this sense, this method possesses intrinsic selectivity for cancer cells with a p53 mutation. Gene therapy with a p53 expressing adenovirus vector was first applied to lung cancer (32), as well as pancreatic cancer (33). Also, a p16 expressing adenovirus vector has also been applied to p16 INK4a/CDKN2 inactivated GI cancers (34, 35).
As mentioned above, these methods have built in selectivity as a nature of the effector, which dramatically reduces the burden of selectivity for safety, which is usually achieved by vector design, and thus provides more freedom for the design of gene delivery methods.
Virus-directed Enzyme/Prodrug Therapy
Virus-directed enzyme/prodrug therapy (VDEPT), also known as suicide gene therapy, is the treatment utilizing the combinations of non-toxic (or less toxic) prodrugs and enzymes to convert a prodrug into its active form leading to a cytocidal effect (31) ( Table II) . Usually, since activated drugs indicate cytotoxicity in a non-selective manner relative to mutation compensation described above, this method is combined with the gene delivery method, which can confer tumor selective gene expression. This way, the toxicity due to the expression of the transgene in an undesired locale can be minimized. To this end, α-fetoprotein promoterbased control has been applied in retroviral expression of thymidine kinase (TK) for hepatoma (36), and carcinoembryonic antigen (CEA) promoter-driven TK expression was applied in pancreatic cancer (37). Among the systems listed in Table II , the selection depends on the biological and physiological features of the target diseases. For example, in the TK-GCV system, the phosphorylated GCV can spread to adjacent cells via gap junction but does not leave the cells. In the CD-5FC system, the activated form (5-FU) can diffuse to the surrounding area. Thus, the TK-GCV system should provide stricter localization while the CD-5FC system would achieve a cytocidal effects in a larger area. These methods exhibit very dependable cytocidal effect in vitro and in vivo as long as the requisite level of activating enzyme expression can be achieved in the target cells. However, these methods require relatively stringent tumor selectivity because the fate of the cells is determined solely by the level of the converting enzyme regardless of the nature of the cells, and it thus puts more burdens to the vector design to confer the requisite selectivity.
Inhibition of Tumor Growth Cell Signals
There are various reports of gene therapy that inhibits cell signals crucial for tumor growth. These strategies can be categorized into three subgroups. The first group is dominant negative (DN) oncogenes, which can block the relevant signal transduction in the cells [e.g., DN-MEKK (138), DN-H-Ras (39)]. The second is blockage of cancer relevant growth factors at receptor level blocking [e.g., NK4: HGF blocker (40, 41)]. In this scheme, the locale of transgene expression does not need to be limited to the target tumor cells as long as the local concentration of the effector reaches an adequate level. The third approach is the use of receptors with anti-tumor effect. In pancreatic cancers, the somatostatin receptor type 2 (SSTR-2) is known to show anti-tumor effect following tumor cell transduction (42, 43) . The first and last groups require transgene expression in the target cancer cells for effect. Thus, they require relatively high transduction efficiency.
Use of Proapoptotic Gene
Various apoptotic inducers have been tested for cancer gene therapy. While these genes are potent inducer of cell death, the majority of these molecules induce apoptotic cell death in a non-selective manner. Thus, once again tumor selectivity needs to be accomplished by targeted gene introduction and/or expression as a vector configuration. In this meaning, targeting plays a major role before the clinical realization of these methods (44). Another technical issue when using viral vectors for the delivery of these genes is that the expression of apoptotic inducers hampers effective propagation of viral vectors in mammalian cells during production. This leads to limited or nonproductive replication of the vectors. To avoid this problem, host cells have been modified to be resistant to the expressed apoptotic inducer (45), while strict switching has been incorporated into the vector system to suppress undesired transgene expression (46, 47) during vector propagation.
Antisense Nucleotides and Ribozymes
Direct blocking of gene function, which is crucial for cancer growth, is by using antisense nucleotides. This is a straightforward approach for the regulation of tumors. Since mutation of Ras is frequently observed in pancreatic cancer patients (48, 49) and is critical for the malignant potential of these cancer cells (50), this gene has been a good target of antisense/ribozyme strategies. While several antisense oligonucleotides and ribozymes have exhibited anti-tumor effects (51-53), function of these agents require high levels of in situ introduction of the nucleotides into each tumor cell. This is one of the major obstacles limiting the clinical application of these methods for cancer patients.
Virotherapy
The fact that many viruses cause cytolysis upon viral replication has been widely known as a virological fact. Thus, it is rational to develop therapeutic modalities for cancers by using such viruses as natural effectors. To this end, various wild type and modified viruses, which possess the ability to replicate selectively in cancer cells, have been used in human clinical trials to achieve selective oncolysis of various neoplasms. Such viruses include adenoviruses (54, 55), mumps virus (56), and West Nile virus (57). More recently parvovirus H-1 (58) and herpes simplex virus (59-63) have been shown to achieve viral oncolysis of tumor cells. Since a major reason for the poor outcomes of cancer gene therapy clinical trials is insufficient transduction of the tumors, virotherapy offers a solution for this problem. As illustrated in Figure 1 , tumor-selective vector replication and lateral spread of the progeny would augment the therapeutic effect (64-67). Adenoviruses were one of the first wild type viruses applied to cancer in the 50's and 60's (54). In this study, no severe adverse effect was observed even though the virus was wild type adenovirus without cancer selectivity. Thus, it provided evidence about the high levels of safety of adenoviral administration and formed the background for virotherapy, while the viruses used did not accomplish the expected therapeutic effect. In the 90's, a rich database for viral vector construction was established as a part of gene therapy development. This advance in virology and accumulated knowledge of vector modification led to the development of an advanced generation of replicative viral agents. Table III , these viral agents possess scientifically designed mechanisms to achieve controlled replication for selective anti-tumor effect and some of these are already in clinical evaluation. In the field of oncolytic adenoviruses, conditionally replicative adenovirus ONYX-015 has been tested by direct injection into the tumor, but did not show a clear therapeutic effect as a single agent (68, 69). New generation virotherapy agents have been developed by employing recent progress of vector technologies. Those viruses will be discussed in a later section.
As shown in

Immunogene Therapy
Immunogene therapy is a method for attacking cancer cells by modulating the host immune system. This type of therapy can be categorized into three groups depending on the methods for immunomodulation: i) enhancement of the host immune-response with various cytokines; ii) immunomodu-lation by expressing epitopes for augmenting anti-tumor immunity; and iii) compensatory expression of down-regulated cell surface proteins for augmenting an immune reaction.
The first approach expects the effect of tumor immunology via tumor-directed cytokine expression mediated by gene transfer (70). There are a large number of experimental applications and some of them, including interferon-β (71), interferon-γ (72), GM-CSF (18), IL-2 (73), and IL-12 (74), have already been used in clinical trials in this category. While many methods of this category use exo vivo gene delivery and administer the cytokine expressing cancer cells after radiating them, some of the protocols use in situ delivery of the gene into the cancer cells. All of these clinical protocols were well tolerated by the patients but their therapeutic outcome was marginal.
The Second approach is a genetic cancer vaccine strategy with certain epitope-encoding vectors/plasmids (75). Tumor associated antigens (TAAs) that are selectively presented on the cancer cells can be exploited to enable the host immune system to recognize the cancer cells as a non-self party. The genes encoding TAAs should be applicable for gene-based vaccines. As an example, various targets including HER-2/neu, MAGE-1, and MUC-1 have been exploited in the field of breast cancer.
The third approach aims at reversing suppressed immunogenicity (especially antigen presentation) of the cancers by expressing the molecules related to the induction of the host immune response. In cancer cells, these molecules are usually suppressed for the survival benefits of the cancer cells as a result of the selection by the host immune system. Exogenous introduction of those genes such as major histocompatibility complex class I (76) and B7.1/B7.2 (77) revert such suppression in the cancer cells and turns them to subjects of immune rejection as a result of the increase of antigen presentation. A similar but slightly different approach is the allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex (78). This system exhibited the regression of the injected lesion in 18% of patients, including one complete response, thus providing a promising approach for certain kinds of cancers.
Antiangiogenesis Therapy
Development of tumor to detectable size always requires neovascularization, where vascular endotherial growth factor (VEGF) plays a key role in recruiting new vessels (79).
Since interfering with this process should lead to the inhibition of tumor progression, the blockade of VEGF can be used for anti-angiogenesis purposes. In the field of pancreatic cancer, a soluble fragment of the VEGF receptor [soluble Flt-1 (30, 80) and Flk-1 (81)] has been applied. Basic principles of antiangiogenesis therapy and its application to brain tumors have been reviewed recently (81A).
Matrix Metalloproteinase Inhibitors
It is known that the matrix metalloproteinase enzymes (MMPs) are involved in the proteolysis of the extracellular matrix, aiding tumor cell invasion and the establishment of metastatic deposits (82). In addition, MMP expression is associated with neovascularization (83), which is required to maintain the blood supply of the growing tumor. Tissue inhibitors of metalloproteinase (TIMP) is a key factor in pancreatic cancer development, which is frequently expressed in the pancreatic cancer lesions and affect the level of MMP activity (84, 85) . Stemming from this biology, the attempt to overturn the balance by overexpressing TIMPs has been successful in mouse models (31, 86, 87).
The above modalities encompass the "payloads" of cancer gene therapy strategies. Some of the approaches are in preparation for or are already in clinical trials. Most of these methods show promise and their combination may provide a more potent and/or specific anti-tumor effect.
Method of Gene Delivery
All gene therapy methods need to achieve a requisite level of gene delivery. On the other hand, some sort of selectivity needs to be achieved to mitigate the toxicity caused by extopic expression of nonspecific effectors. As mentioned in the report of the NIH special panel in 1995 (88), current vector systems still have problems, and numerous efforts have been made to overcome those hurdles since then.
Transduction Efficiency
Despite a high degree of optimism, cancer gene therapy clinical trials carried out so far have fallen short of their therapeutic expectations. In these trials, it was demonstrated that limited tumor transduction represents a fundamental barrier for the complete realization of the full benefits of cancer gene therapy (19) (20) (21) (22) . This point is axiomatic since any gene therapy approach is fundamentally based on the ability to deliver the therapeutic gene to target cells and express it as an effector (19, 20, 23, 24) . The exploitation of gene therapy in this field requires considerably high transduction efficiency since residual cancer cells as a result of insufficient transduction leads to the relapse/regrowth of the tumor. In general, viral vectors tend to have higher transduction efficiency in comparison with non-viral methods so far. Thus, virus-derived vectors tend to be preferred more frequently than non-viral vectors.
There are two viral vectors, which have been widely used for gene delivery for cancer gene therapy; the adenovirus-based system (89) and the herpes simplex virus based system (66). Adenoviral vectors have been extensively used because of its high infectivity in a relatively wide range of tumor types (90). However, the transduction of some kinds of cancer cells is poor due to the paucity of the primary adenovirus receptor, coxsackie-adenovirus receptor (CAR) (90). However, since low CAR expression is typical for many solid tumors (91) (92) (93) , CAR-independent adenoviral infection needs to be achieved to overcome this issue. Interestingly, adenovirus has considerable versatility in the context of tropism alternation conferred by capsid modification. In particular, the fiber-knob region of adenovirus has several sites which accept the incorporation of extrinsic peptide sequences for binding [e.g., HI-loop (94), c-terminal (95)]. When an RGD motif which binds to integrins was incorporated into the HI-loop of the fiber knob region, the resultant vector showed dramatically enhanced transduction in CARnegative cells via initial binding to integrins, instead (96). In the replicative virus-based system, infectivity of the progeny virus is one of the most important determining factors for the potency of replicative agents. Thus, it is reasonable that the application of the above mentioned infectivity enhancement in CRAds [e.g., RGD-modified ∆24 (97, 98) and COX-2 CRAds (99)] showed dramatically enhanced antitumor effects in vivo. Thus, infectivity enhancement is also a rational design for replicative agents. In the case of herpes simplex virus, while replication competent herpes simplex virus has been successfully applied to some cancers (see details in Virotherapy section), suboptimal in vivo viral replication remain a barrier that limits the full potential of this system (66). Manipulating the virus surface in order to achieve infectivity enhancement is not easy due to its relatively complex infection mechanism. However, attempts to incorporate a syncytium-forming property might be practical to circumvent this problem (100). With regard to nonreplicative HSV vectors (amplicons), their application has been limited to vaccination purposes (101). Further improvement of HSV transduction efficiency may be required for direct transduction of the cancer cells.
For any vector types, higher transduction efficiency would help reduce an innate immune response to the vector, since such a vector enables reduction of the vector administration dose. While there was a case of patient death due to innate immune response imposed by high administration dose, excessive transduction efficiency has not shown any clinical harm during cancer gene therapy. Based on the limitations outlined above, transduction improvements will clearly be needed to realize the benefits of gene therapy in the field of cancer. However, increased infectivity of the tumor may also augment transduction of normal cells; as a result, more stringent selectivity may be required to maintain safety when using infectivity enhanced vectors. This balance between transduction efficiency and selectivity (next part) will be very important for the clinical utility of these new therapeutic modalities.
Selectivity
The ultimate goal of cancer gene therapy is selective removal of cancer cells without harming the normal cells. In this sense, we need to limit the effect of the treatment (usually cytocidal) to cancer cells to avoid adverse effects. Some gene therapy strategies based on the transgenes which do not show toxicity in non-cancer cells (such as p53) can be configured without incorporating vector based selectivity (25). On the other hand, if the effector shows a non-specific cytocidal effect, some kind of selectivity feature will definitely be needed for mitigating toxicity in normal tissues/organs. For instance, in suicide gene therapy with herpes simplex virus thymidine kinse (HSV-TK) as a transgene, virtually all cells whose HSV-TK expression is higher than threshold will be killed after administration of GCV. Thus, tumor specific expression of the effector is absolutely required to confer specific killing of cancer targets. In the case of adenoviral vectors, the vast majority of the vector injected or released into circulation localizes to the liver (102). As a result, TK expressing adenoviral vectors controlled with ubiquitous promoter (e.g., cytomegalovirus immediate early promoter) showed lethal toxicity after administration of GCV (103). This toxicity can be mitigated by using a selective promoter which is minimally active in the liver (e.g., COX-2 promoter) (103). These results clearly indicate the importance of selective expression of a toxic transgene for safety.
Selective expression of the effector can be achieved both transcriptionally and transductionally. Because the goal of targeting is to achieve maximal contrast between cancer cells and background normal cells, the requirements for targeting are: i) high transgene expression at the requisite level for therapeutic effect and ii) minimal expression in background organs to avoid toxicity. Transcriptional targeting utilizes selective promoters for the control of expression. Numerous promoters selectively activated in cancer cells (so-called tumor specific promoters) have been used to achieve this goal (104). In most cases, the promoters isolated and characterized in the plasmid usually show the promised expression profile in plasmidbased vector configuration. This approach has also been applied to selective gene expression for viral vectors including retrovirus (105), adenovirus (106), and HSV (107). In the field of adenoviral vectors, various tumor specific promoters have been tested and many of them achieved a level of tumor selectivity, and additional promoters have been applied in this context recently. These include (but not limited to) the promoters of tyrosinase (108), L-plastin (109), DF3/Muc-1 (110), myelin basic protein (111), midkine (112), cyclooxygenase-2 (103), thyroglobulin (113), caveolin-1 (114), human-telomerase (115), and secretory leukoprotease inhibitor (116). During this process, it was observed that that the promoter placed in viral vectors sometimes exhibit an unexpectedly leaky profile (117). This phenomenon has been understood as an effect of the strong enhancer activity of the packaging signal region and cryptic transcription initiation sites in the vector (118, 119) . One solution to enhance the fidelity of the promoter is to place an insulator between the viral sequence and expression cassette (118, 120) . Another approach is to move the enhancer/packaging signal to the right end of the viral genome (121) which helps to lower expression of the transgene from cryptic promoter sequences (119).
Transductional targeting achieves selectivity at the level of gene delivery. This method has been the most frequently pursued in adenoviral vectors since this vector enters target cells via a well-defined mechanism based on protein-protein interaction. There are two strategies in this targeting category. The first one is positively targeting the vector to the desired cells by incorporation of a targeting motif in the vector capsid proteins (122-124), using an antibody with targeting capability (125), or substituting the fiber with that of another serotype fiber to achieve different tropism (126) (127) (128) . The second transductional targeting approach is to improve the tumor/background ratio by reducing vector distribution to normal organ and/or increasing tumor transduction. Several vectors with capsid mutation to reduce the viral binding onto the cells based on the native hepato-tropism have been reported (129, 130) .
In many cancers, the expression of the receptors mediating vector entry is not necessarily suitable for tumor targeting. Concerning adenovirus, many cancers including many gastrointestinal cancers and prostate cancers show relative paucity of its primary receptor (coxsackie-adenovirus receptor, CAR). In this sense, some kind of method to enable CARindependent infection is necessary for the realization of cancer gene therapy in those cancers. Wesseling et al. (92) reported infectivity enhancement in pancreatic cancer cells by incorporating an RGD-4C motif into the adenoviral fiber (described in the transduction efficiency section) and Davydova et al. (91) reported the enhancement with Ad5/3 chimeric adenoviral fiber in esophageal adenocardinoma. These methods also dramatically enhances the effect of replication competent adenovirus in CAR-negative cancers (91, 99) .
In addition to adenovirus, retargeting of two enveloped vectors were reported recently: one is lentivirus retargeted by Sindbis virus pseudo typing (131) and the other is measles virus by incorporating chimeric H-protein with single-chain antibody (132). These vector targeting technologies are powerful and versatile.
In summary, these targeting strategies are crucial for achieving potent and selective antitumor effect and thus will play an indispensable role for clinical realization of cancer gene therapy.
Non-viral Gene Delivery
A big advantage of non-viral gene delivery is that this system minimally invokes vector-derived immunogenicity in comparison to viral vectors which are widely known to induce various levels of immune reaction against viral components of the vectors. So far, the efficiency of non-viral gene delivery method is lower than viral techniques. One possible reason is inefficient nuclear transport of the gene after entry. While several efforts to improve nuclear localization have been made, reports of in vivo utility of nonviral gene delivery systems in the field of cancer gene therapy are limited. In several instances, this method was applied for the delivery of oligonucleotides (e.g., antisense oligonucleotide, ribozyme) and showed in vivo efficacy after intraperitoneal administration (51, 133, 134) , suggesting that the enclosed environment of the administration site may have enhanced the delivery efficiency.
Non-replicative Viral Vectors
A number of non-replicative viral vectors have been used for cancer gene therapy. A retroviral vector was used for in vivo transduction by inoculating retroviral packaging cell lines for in situ vector production in order to compensate the relatively low in vivo transduction efficiency after direct vector administration (135). In the current retroviral system, in vivo transduction efficiency will need to be improved for clinical feasibility based on in situ transduction. Adenoviral vectors have been used most frequently for cancer gene therapy since their transduction efficiency in many cancer cells is relatively high in comparison to other vectors. However, as stated above, their efficiency in some CAR-negative cancer cells is still much lower than the level required for the ther-apeutic outcome. This was thought to be due to the paucity of the primary receptor, CAR, expression (92). Of all viral vectors, this vector is the most advanced in the context of vector modification because of its relatively simple infection process mediated by protein-protein interaction and also the rich background information accumulated from the long history of adenovirus virology (136). In this meaning, various retargeting efforts have been conducted. For example in the field of pancreatic cancer, antibody based targeting [FGF receptor (137) ] and fiber modification-based infectivity enhancement 99) ] were reported. Adeno-associated viral vectors have the advantage of longterm expression of transgenes (138).
Currently, all viral vector systems have pros and cons. In other words, there is no single vector which serves for every cancer context. In this meaning, choice of the optimal vector which best fits to the goal of the therapy is a key for success.
Gene Therapy Based on Replicative Viruses
So far, no gene delivery strategy can achieve transduction of 100% of tumor cells. It is thus clear that the therapeutic effectors need to be functional not only in the initially transduced cells but also in the surrounding cancer cells. In this sense, strategies with a so-called "bystander effect" or those that use an indirect anti-tumor effect via host cell modulation have potential benefits to achieve such widespread outcomes. Virotherapy is one of such strategies. In virotherapy, the oncolytic virus replicates in the target cancer cells and exhibits a cytocidal effect as a part of viral replication cycle. The target cancer cells are not only killed, but also function as a factory for the production of the next generation of the progeny virus (64). The extent of replicative virus spread would easily exceed the bystander effect accomplished through gap junction mediated transportation or secretion of the effectors. Various viruses including adenovirus (68, 99, 139), herpes simplex virus (61, 140, 141), Newcastle Disease Virus (142), and reovirus (143) are reported to be effective in mouse xenograft models and some of them were tested in human.
When adenovirus, dl1520 (ONYX-015), was applied in head and neck cancers, it showed a promising clinical trial outcome (144). In pancreatic cancers, it did not show a clear therapeutic benefit by CT-guided or intraoperative injection (phase I) (68), endoscopis ultrasonography (EUS) guided injection (phase I/II) (69). While the therapeutic regime was well tolerated in all those protocols, no viral replication was detected. The CAR expression in some cancers, including pancreatic cancer, tends to be minimal (see details in the Transduction Efficacy section), and therefore this deficiency would hamper secondary infection by progeny virus. In CAR-negative cancer cells, it has been reported that infectivity enhancement based on the introduction of an RGD-4C motif in the HI-loop of the fiber knob region (RGD modification) and replacement of knob region with Ad3 knob (Ad5/3 chimera) enhanced infectivity via CAR independent infection (91, 92) . This method was successfully applied to conditionally replicative adenoviruses (CRAds) and dramatically enhanced the anti-tumor effect in a subcutaneous xenograft model of human lung and pancreatic cancers (98, 99) . These reports provide a proof-of-principle of the beneficial attributes of infectivity enhanced CRAds.
The broadening of the range of the transducible cell population by means of infectivity enhancements also may possibly mean more transduction of background tissues, and thus, requires a higher level of selectivity for the safety of replicative vectors to avoid the problem of undesired replication in normal tissues (64, 65) . Several methods have been proposed to increase the selectivity of CRAds. One technique is optimization of tumor specific promoter (TSP) in promoter-controlled E1 expression type CRAds. There are many promoters which are potentially applicable for the construction of CRAd-based cancer therapeutics. However, some of them are too weak to drive effective viral replication while some become leaky when configured in an adenovirus vector (especially in CRAds). Amongst the candidates, several promoter including the COX-2 promoter showed a very high level of promoter activity comparable to that of the CMV promoter but the activity in the liver is more than four orders lower than that of the CMV promoter (103). Because adenoviral vectors are associated with hepatotoxicity, low promoter activity in the liver is required to avoid this complication (99).
A second strategy in the design of CRAds is to mutate the E1 region so that the defect could only be compensated in a tumor cell environment. Based on this scheme, a virus with a 24 bp deletion in the CR2 (∆24) and the one with additional 54 amino acid deletion in CR1 region (CB016) have been proposed as a selective oncolytic agents (145, 146) .
In addition to these technologies, several new approaches have been reported recently. One such method utilizes the COX-2 3'-UTR region to provide differential RNA stability depending on the target cell's Ras activity (147). Another method relies on the mutation of virus-associated (VA) RNAs that are necessary for inactivating protein kinase R (PKR) to avoid an interferon response and promote viral replication. VA RNA mutant viruses can not inactivate PKR; therefore, viral replication occurs only in cells where PKR is inhibited through such mechanisms as Ras activation (148). Because activating K-Ras mutation is one of the most frequently observed genetic phenomenon in pancreatic cancers, these strategies are suitable for pancreatic cancer CRAds.
These CRAds were designed based on critical virological and oncological features of adenovirus and pancreatic cancer in order to achieve more selectivity as well as potency. The combination of these strategies may achieve new generation CRAds with better therapeutic profiles.
More than twenty HSV-based oncolytic viruses have been reported for the treatment of cancer (66), including hrR3 (ICP-6 inactivation) (149), NV1020/R7020 (Deletion of UL-US joint region including one γ34.5) (150), and G207 (ICP-6 inactivation and deletion of both γ34.5) (140). First generation vectors showed initial promise in various cancers [hrR3 (149) and NV1020 (150)]. A second generation HSV vector, G207, contains multiple mutations to increase safety (140). In Aotis nancymai, a New World owl monkey, inoculation of 10 9 plaque forming unit (pfu) of G207 did not cause any adverse effects even after intracerebral injection, while the parental F strain caused lethal encephalitis at a dose of 10 3 pfu (151). The efficacy and safety data for replicative herpes virus vectors are still accumulating. Although these studies established feasibility and key fundamentals for the utility of replication competent HSV vectors for the therapy of a variety of cancers, further improvement may be needed for the following fields (66). The first is the improvement of targeting. While transductional targeting of HSV has been difficult because of a complex mechanism of infection, transcriptional targeting by using tumor specific promoters has led to some successful vectors. The second point is suboptimal spread of newly replicated virus as a result of the complex configuration of tumors with physical barriers preventing viral spread. The third is neurovirulence. Even though second generation vectors (e.g., G207) showed a nice safety profile in a very sensitive experimental owl monkey model, toxicity issues may still arise if less attenuated viruses need to be used to achieve stronger antitumor effects. In the aggregate, replication competent HSV vectors provide high promise for the treatment of solid tumors but still there is a room for improvement.
Reovirus is a double stranded RNA virus commonly isolated from the respiratory and gastrointestinal tract of humans (152). The most interesting molecular biology feature of this virus is that it requires activated Ras for replication (153). Based on this fact, cancers with Ras activating mutations are considered to be good targets of this virus.
Theoretically, many viruses of human and other species origin have potential as a therapeutic agent for cancer. Since the power of replicative viral agents has been clearly validated, other viruses including modified versions of existing viral agents will perhaps be further applied in the same manner.
Surrogation Endpoint
The purpose of cancer gene therapy is to eradicate tumors, and thus the ultimate goal is to achieve an antitumor effect. To this end, the endpoint assay in clinical application is to be the anti-tumor effect. However, during clinical trials, functionality of therapeutic modality needs to be monitored as a predicting factor for anti-tumor effect as well as an indicator to foresee the possibility of adverse effects. In addition, information gathered in the process of clinical trials should improve our understanding of the biological behavior of these therapies in the human body and help future improvements. These assays should be informative yet minimally invasive. For example, if the expression of TK could be monitored in normal organs, administration of the prodrugs could be halted in case an undesired expression profile is observed. Such detection of transgene expression was performed by immunobloting or immunohistochemistry in biopsy specimens in previous studies (154) . Although biopsy examination is informative, it is invasive and the validity of the assay largely depends on the accessibility of the target organs to be tested. In some cancers (e.g., pancreatic cancer), biopsy evaluations would be difficult due to the limited accessibility of the organ.
Several efforts have been made to overcome this obstacle. One strategy is to utilize a secretable marker gene that could be detectable in the blood (155). A soluble human carcinoembryonic antigen (shCEA) and β subunit of human chorionic gonadotropin (βhCG) was successfully used to monitor tumor selective replication of an Edmonston-strain measles virus. While monitoring of secretory markers is a convenient way to assure the vector functionality in clinical trials, it does not give valid information about the localization of gene expression, which is supposed to be important for predicting possible adverse effect. On the other hand, imaging will provide the information of localization while the monitoring procedure may become cumbersome in comparison with blood tests. Various established methods can be applied to the monitoring of transgene expression and/or viral replication. Radiological imaging utilizes radiolabeled substrates to represent the localization of transgene expression by using radiolabeled prodrugs to image the localization of converting enzyme [e.g., FIAU (156, 157) , GCV (158, 159) for TK] or radiolabeled ligand to image the localization of receptors [ligand peptides for somatostatin receptor-2 (160) and dopamine receptor (161)]. The labeling with γ-ray emitter [e.g., 131 I, 99m Tc) enables detection with γ-camera and SPECT (157), while labeling with positron (e.g., 18 F, 124 I) enables detection with PET (161). Some of the radiolabeled ligand peptides are already approved for clinical use in receptor imaging. In addition to radiological imaging, optical imaging offers a promise. Fluorescent proteins such as green fluorescent protein (GFP) have been used for in vitro imaging for a long time and were recently applied for in vivo imaging. While this method does not require the tracer or substrate administration for obtaining fluorescence, it does require an excitation of a certain wavelength. Recently developed fluorescent proteins with red fluorescence (e.g., RFP) could minimize non-target tissue absorption (162).
Alternatively, luminescence-based optical imaging utilizing luciferase genes can be applied for this purpose (163, 164) . While this method requires the administration of substrates, it has very high sensitivity relative to fluorescence imaging. In mice, luminescence imaging has been performed with minimal toxicity; however, its use as well as the application of fluorescence imaging has yet to be validated in humans. Both radiological and optical imaging techniques offer a promising opportunity to provide a valid interval endpoint yielding data, which generally benefit clinical trials. The establishment of these methods will also be informative with regards to the in vivo property of gene therapy methods. Overall, the wealth of the data from monitoring tools will not only help the planning of safer clinical trials but also provide key information for future vector development.
Intellectual Property and Cost of Clinical Trials
Intellectual property issues should not affect the academic pursuit of science. However, in the field of gene therapy, we are trying to develop a method for treating patients. Considering the cost of clinical trials, at some point there is need for financial support from the private sector with an expectation of future commercialization. On the other hand, improvement of the design of the therapeutic modality often requires a combination of multiple optimized components. In this scenario with intellectual property issue the commercial sector may hesitate to invest.
The National Cancer Institute established a program called Rapid Access to Intervention Development (RAID) in 1998 to enable clinical translation of novel, scientifically meritorious therapeutic interventions originating in the academic community. This mechanism should assist the development of novel gene therapy modalities by supporting investigatorinitiated clinical trials. It is hoped that the expansion of such a system will boost the efforts of the academic researchers to develop the next generation of gene therapeutics for cancer.
Conclusion
Cancer gene therapy has not met the initial high expectation. Many experiments and clinical trials have identified current obstacles to the realization of an effective cancer gene therapy modality. Tireless efforts to overcome such hurdles and continuous infusion of novel concepts into this field should lead to break through technologies and cure of cancer. 
